TY - JOUR
T1 - A Phase II Trial of Temozolomide and IFN-α in Patients with Advanced Renal Cell Carcinoma
AU - Sunkara, Usha
AU - Walczak, Janet R.
AU - Summerson, Lori
AU - Rogers, Theresa
AU - Eisenberger, Mario
AU - Denmeade, Samuel
AU - Pili, Roberto
AU - Huff, Carol Ann
AU - Sinibaldi, Victoria
AU - Carducci, Michael A.
PY - 2004/1
Y1 - 2004/1
N2 - The combination of temozolomide (TEM) and interferon-α (IFN-α) previously demonstrated a 30% response rate in metastatic melanoma. A single institution, phase II trial evaluating the efficacy of TEM/IFN in patients with advanced renal cell carcinoma (RCC) was conducted. Safety and tumor response were the main outcomes. Eligible patients received 200 mg/m2/day TEM orally on days 1-5 every 28 days, with IFN 2.5 million U/m2/day subcutaneously (s.c.) three alternate days/week for days 1-15 first cycle, then 5 million U/m2/day s.c. 3 alternate days/week throughout each 28-day cycle. Efficacy was evaluated every 8 weeks, and dose-limiting toxicities (DLTs) were treated with dose reductions of the culprit drug. Sixteen patients (ages 37-67) were initially enrolled. Of the 14 evaluable patients, there was one minor response. Best response was stable disease, with 7 patients remaining on study for ≥6 months. Five were alive for more than 2 years, and 2 remain alive at 45 and 50 months after enrollment. DLTs included TEM-induced myelosuppression and IFN-induced fever/chills. Other toxicities were mild to moderate (grades 1-3). The combination of TEM/IFN proved quite tolerable. This regimen appears inactive in terms of response in this population with poor prognosis, but the patients with stable disease ≥6 months remain of interest.
AB - The combination of temozolomide (TEM) and interferon-α (IFN-α) previously demonstrated a 30% response rate in metastatic melanoma. A single institution, phase II trial evaluating the efficacy of TEM/IFN in patients with advanced renal cell carcinoma (RCC) was conducted. Safety and tumor response were the main outcomes. Eligible patients received 200 mg/m2/day TEM orally on days 1-5 every 28 days, with IFN 2.5 million U/m2/day subcutaneously (s.c.) three alternate days/week for days 1-15 first cycle, then 5 million U/m2/day s.c. 3 alternate days/week throughout each 28-day cycle. Efficacy was evaluated every 8 weeks, and dose-limiting toxicities (DLTs) were treated with dose reductions of the culprit drug. Sixteen patients (ages 37-67) were initially enrolled. Of the 14 evaluable patients, there was one minor response. Best response was stable disease, with 7 patients remaining on study for ≥6 months. Five were alive for more than 2 years, and 2 remain alive at 45 and 50 months after enrollment. DLTs included TEM-induced myelosuppression and IFN-induced fever/chills. Other toxicities were mild to moderate (grades 1-3). The combination of TEM/IFN proved quite tolerable. This regimen appears inactive in terms of response in this population with poor prognosis, but the patients with stable disease ≥6 months remain of interest.
UR - http://www.scopus.com/inward/record.url?scp=9144222966&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=9144222966&partnerID=8YFLogxK
U2 - 10.1089/107999004772719891
DO - 10.1089/107999004772719891
M3 - Article
C2 - 14980083
AN - SCOPUS:9144222966
SN - 1079-9907
VL - 24
SP - 37
EP - 41
JO - Journal of Interferon and Cytokine Research
JF - Journal of Interferon and Cytokine Research
IS - 1
ER -